555 related articles for article (PubMed ID: 28615371)
21. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.
Göke F; Franzen A; Menon R; Goltz D; Kirsten R; Boehm D; Vogel W; Göke A; Scheble V; Ellinger J; Gerigk U; Fend F; Wagner P; Schroeck A; Perner S
Chest; 2012 Oct; 142(4):1020-1026. PubMed ID: 22499828
[TBL] [Abstract][Full Text] [Related]
22. FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway.
Ji W; Yu Y; Li Z; Wang G; Li F; Xia W; Lu S
Oncotarget; 2016 Mar; 7(12):15118-34. PubMed ID: 26936993
[TBL] [Abstract][Full Text] [Related]
23. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Chae YK; Hong F; Vaklavas C; Cheng HH; Hammerman P; Mitchell EP; Zwiebel JA; Ivy SP; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Mansfield A; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
J Clin Oncol; 2020 Jul; 38(21):2407-2417. PubMed ID: 32463741
[TBL] [Abstract][Full Text] [Related]
24. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
[TBL] [Abstract][Full Text] [Related]
25. FGFR1 Amplification in Squamous Cell Carcinoma of the Lung with Correlation of Primary and Metastatic Tumor Status.
Monaco SE; Rodriguez EF; Mahaffey AL; Dacic S
Am J Clin Pathol; 2016 Jan; 145(1):55-61. PubMed ID: 26712871
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast growth factor receptors 1 and 4 combined with lymph node metastasis predicts poor prognosis in oral cancer.
Gu ZY; Zhou R; Hong D; Han Y; Wang LZ; Li J; Zhang ZY; Shi CJ
Oral Dis; 2024 Apr; 30(3):1004-1017. PubMed ID: 36938639
[TBL] [Abstract][Full Text] [Related]
27. Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
Usul Afsar C; Sahin B; Gunaldi M; Kılıc Bagir E; Gumurdulu D; Burgut R; Erkisi M; Kara IO; Paydas S; Karaca F; Ercolak V
Int J Clin Exp Pathol; 2015; 8(9):9760-71. PubMed ID: 26617686
[TBL] [Abstract][Full Text] [Related]
28. Complexity of FGFR signalling in metastatic urothelial cancer.
Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of Primary Drug Resistance in
Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
[No Abstract] [Full Text] [Related]
30. FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
Luo H; Quan J; Xiao H; Luo J; Zhang Q; Pi G; Ye Y; He R; Liu Y; Su X; Zhao L; Wang G
Oncol Rep; 2018 May; 39(5):2270-2278. PubMed ID: 29517107
[TBL] [Abstract][Full Text] [Related]
31. FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer.
Flockerzi FA; Roggia C; Langer F; Holleczek B; Bohle RM
Virchows Arch; 2018 May; 472(5):759-769. PubMed ID: 29270870
[TBL] [Abstract][Full Text] [Related]
32. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck.
Clauditz TS; Böttcher A; Hanken H; Borgmann K; Sauter G; Wilczak W; Grob T; Münscher A
J Cancer Res Clin Oncol; 2018 Jan; 144(1):53-61. PubMed ID: 29022097
[TBL] [Abstract][Full Text] [Related]
34. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
Hong DS; Moore K; Patel M; Grant SC; Burris HA; William WN; Jones S; Meric-Bernstam F; Infante J; Golden L; Zhang W; Martinez R; Wijayawardana S; Beckmann R; Lin AB; Eng C; Bendell J
Clin Cancer Res; 2018 Jul; 24(14):3263-3272. PubMed ID: 29643063
[No Abstract] [Full Text] [Related]
36. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
Malchers F; Nogova L; van Attekum MH; Maas L; Brägelmann J; Bartenhagen C; Girard L; Bosco G; Dahmen I; Michels S; Weeden CE; Scheel AH; Meder L; Golfmann K; Schuldt P; Siemanowski J; Rehker J; Merkelbach-Bruse S; Menon R; Gautschi O; Heuckmann JM; Brambilla E; Asselin-Labat ML; Persigehl T; Minna JD; Walczak H; Ullrich RT; Fischer M; Reinhardt HC; Wolf J; Büttner R; Peifer M; George J; Thomas RK
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37606995
[TBL] [Abstract][Full Text] [Related]
37. CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for
Yang Z; Liang SQ; Yang H; Xu D; Bruggmann R; Gao Y; Deng H; Berezowska S; Hall SRR; Marti TM; Kocher GJ; Zhou Q; Schmid RA; Peng RW
Cancer Res; 2021 Jun; 81(11):3121-3133. PubMed ID: 33685992
[TBL] [Abstract][Full Text] [Related]
38. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
Liang D; Chen Q; Guo Y; Zhang T; Guo W
Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.
Tran TN; Selinger CI; Kohonen-Corish MRJ; McCaughan BC; Kennedy CW; O'Toole SA; Cooper WA
Lung Cancer; 2013 Sep; 81(3):462-467. PubMed ID: 23806793
[TBL] [Abstract][Full Text] [Related]
40. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
Ren S; Rivard CJ; Yu H; Genova C; Rozenboom L; Gao D; Hinz TK; Rikke BA; Wynes MW; Caldwell C; Agustoni F; Kenichi Suda ; Jiang T; Zhou C; Heasley LE; Hirsch FR
Clin Lung Cancer; 2018 Sep; 19(5):450-456. PubMed ID: 30146263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
